KR20180101643A - 매크로라이드의 결정 형태들 및 그 용도들 - Google Patents

매크로라이드의 결정 형태들 및 그 용도들 Download PDF

Info

Publication number
KR20180101643A
KR20180101643A KR1020187025895A KR20187025895A KR20180101643A KR 20180101643 A KR20180101643 A KR 20180101643A KR 1020187025895 A KR1020187025895 A KR 1020187025895A KR 20187025895 A KR20187025895 A KR 20187025895A KR 20180101643 A KR20180101643 A KR 20180101643A
Authority
KR
South Korea
Prior art keywords
cem
water
solution
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187025895A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 이. 페레이라
Original Assignee
셈프라 파마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180101643(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셈프라 파마슈티컬스, 인크. filed Critical 셈프라 파마슈티컬스, 인크.
Publication of KR20180101643A publication Critical patent/KR20180101643A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020187025895A 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들 Ceased KR20180101643A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127027222A Division KR102006200B1 (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Publications (1)

Publication Number Publication Date
KR20180101643A true KR20180101643A (ko) 2018-09-12

Family

ID=44673574

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187025895A Ceased KR20180101643A (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들
KR1020127027222A Expired - Fee Related KR102006200B1 (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127027222A Expired - Fee Related KR102006200B1 (ko) 2010-03-22 2011-03-22 매크로라이드의 결정 형태들 및 그 용도들

Country Status (19)

Country Link
US (4) US8975386B2 (https=)
EP (2) EP3009442B1 (https=)
JP (4) JP5711352B2 (https=)
KR (2) KR20180101643A (https=)
CN (2) CN108570083A (https=)
AU (2) AU2011232627B2 (https=)
BR (1) BR112012023950A2 (https=)
CA (1) CA2793884C (https=)
DK (1) DK2550286T3 (https=)
ES (1) ES2564097T3 (https=)
HR (1) HRP20160168T1 (https=)
IL (1) IL222018B (https=)
MX (1) MX361413B (https=)
MY (1) MY162411A (https=)
NZ (1) NZ602544A (https=)
PL (1) PL2550286T3 (https=)
RU (1) RU2650883C2 (https=)
SI (1) SI2550286T1 (https=)
WO (1) WO2011119604A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
DK2550286T3 (en) * 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
CN105198944B (zh) 2010-05-20 2018-06-01 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru) 2013-03-15 2017-04-24 Семпра Фармасьютикалс, Инк. Конвергентные способы получения макролидных антибактериальных агентов
US9982005B2 (en) 2013-04-04 2018-05-29 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
KR20170039689A (ko) * 2014-08-05 2017-04-11 셈프라 파마슈티컬스, 인크. 항균제의 분말 경구 현탁제 제형
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
JP2018509452A (ja) 2015-03-25 2018-04-05 プレジデント アンド フェローズ オブ ハーバード カレッジ 修飾デソサミン糖をもつマクロライドおよびその使用
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
CN115003309B (zh) 2019-12-02 2024-05-24 阿里量子解决方法公司 一种具有结构式i的化合物的晶型

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
DE69733723T2 (de) 1996-09-04 2006-04-20 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
CZ9904388A3 (cs) 1997-06-11 2002-10-16 Pfizer Products Inc. 9-Oximové deriváty erythromycinu
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
TR200102129T2 (tr) 1998-12-10 2002-01-21 Pfizer Products Inc. Karbamat ve karbazat ketolid antibiyotikleri.
CA2359708C (en) 1999-01-27 2005-10-25 Pfizer Products Inc. Ketolide antibiotics
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
IL145976A0 (en) 1999-04-16 2002-07-25 Ortho Mcneil Pharm Inc Ketolide antibacterials
ID30547A (id) 1999-04-16 2001-12-20 Kosan Biosciences Inc Zat anti-infeksi makrolida
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ATE297941T1 (de) * 2000-03-15 2005-07-15 Hanmi Pharm Ind Co Ltd Verfahren zur herstellung von einer kristallinen form ii von clarythromycin
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
PT1320355E (pt) 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
WO2003004509A2 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
BR0307898A (pt) 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
SI1742957T1 (sl) 2004-04-28 2008-04-30 Alembic Ltd Postopek za pripravo telitromicina
JP2008508322A (ja) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
UA85937C2 (uk) * 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди
EP1835921B1 (en) 2005-01-14 2010-08-18 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
US20110040078A1 (en) * 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
CN105732745A (zh) 2007-10-25 2016-07-06 森普拉制药公司 大环内酯类抗菌剂的制备方法
AU2009308182B2 (en) * 2008-10-24 2016-05-19 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
PL2544537T3 (pl) 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
DK2550286T3 (en) * 2010-03-22 2016-02-29 Cempra Pharmaceuticals Inc CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
RU2650883C2 (ru) 2018-04-18
US8759500B2 (en) 2014-06-24
CA2793884A1 (en) 2011-09-29
CA2793884C (en) 2019-09-10
AU2016203986A1 (en) 2016-06-30
PL2550286T3 (pl) 2016-07-29
AU2011232627A1 (en) 2012-10-18
JP2017081953A (ja) 2017-05-18
JP6121387B2 (ja) 2017-04-26
JP2015063536A (ja) 2015-04-09
EP3009442A1 (en) 2016-04-20
EP2550286A4 (en) 2013-10-02
KR20130056226A (ko) 2013-05-29
EP3009442B1 (en) 2019-06-19
MX2012010895A (es) 2013-02-15
AU2016203986B2 (en) 2016-10-06
MX361413B (es) 2018-12-05
US8975386B2 (en) 2015-03-10
BR112012023950A2 (pt) 2016-07-05
JP5711352B2 (ja) 2015-04-30
JP2013522367A (ja) 2013-06-13
HK1177937A1 (en) 2013-08-30
HRP20160168T1 (hr) 2016-03-25
IL222018B (en) 2019-05-30
EP2550286B1 (en) 2015-12-09
SI2550286T1 (sl) 2016-04-29
NZ602544A (en) 2014-11-28
AU2011232627B2 (en) 2016-03-17
CN108570083A (zh) 2018-09-25
JP2020002168A (ja) 2020-01-09
US20190040096A1 (en) 2019-02-07
US20130252915A1 (en) 2013-09-26
KR102006200B1 (ko) 2019-08-01
WO2011119604A1 (en) 2011-09-29
MY162411A (en) 2017-06-15
DK2550286T3 (en) 2016-02-29
US20130018008A1 (en) 2013-01-17
RU2012144614A (ru) 2014-04-27
US20160244472A1 (en) 2016-08-25
CN103080122A (zh) 2013-05-01
EP2550286A1 (en) 2013-01-30
ES2564097T3 (es) 2016-03-17

Similar Documents

Publication Publication Date Title
KR102006200B1 (ko) 매크로라이드의 결정 형태들 및 그 용도들
AU2020262100B2 (en) A 7H-pyrrolo[2,3-d]pyrimidine JAK-inhibitor
MX2014005362A (es) Forma iv del clorhidrato de ivabradina.
US9593117B2 (en) Crystalline form of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
SK283735B6 (sk) Forma VI 5,6-dichlór-2-(izopropylamino)-1-(beta-L-ribofuranozyl)- 1H-benzimidazolu, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
US10221185B2 (en) Crystal form of substituted aminopyran derivativek
CN119630666A (zh) 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用
HK1221229B (en) Crystalline forms of a macrolide, and uses therefor
HK1221229A1 (en) Crystalline forms of a macrolide, and uses therefor
HK1177937B (en) Crystalline forms of a macrolide, and uses therefor
CN107474057B (zh) (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
HK1182115A (en) Crystalline forms of a macrolide, and uses therefor
CN104098575B (zh) 一种盐酸依匹斯汀晶型及其制备方法和用途
WO2025032195A1 (en) Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate
HK40036995A (en) Crystals of glycyrrhizic acid derivatives, crystalline compositions, pharmaceutical compositions and uses thereof
CZ20003709A3 (cs) Nové krystalické formy protivirivé benzimidazolové sloučeniny

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180906

Application number text: 1020127027222

Filing date: 20121018

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181210

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190214

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181210

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I